Efficacy and Safety of Radiotherapy in Oligoprogressive HCC Following First-line PD-1 Therapy

This study is testing whether adding targeted radiation therapy to a small number of growing tumor spots (called oligoprogression) can help people with liver cancer (hepatocellular carcinoma, HCC) whose disease had previously been stable on immunotherapy (PD-1 treatment) but is now partially progressing. **You may be eligible if...** - You are between 18 and 75 years old - You have a confirmed diagnosis of liver cancer (HCC) - Your cancer was stable for at least 3 months on immunotherapy (PD-1 therapy) but now has limited progression (5 or fewer new or growing spots in 3 or fewer organs) - You have not previously received radiation therapy for your liver cancer - You are in good health (ECOG performance status 0 or 1) and have a life expectancy of at least 6 months **You may NOT be eligible if...** - Your HCC is a rare subtype (fibrolamellar, sarcomatoid) or is actually bile duct cancer - You have a history of liver failure or previous liver transplant - You have significant fluid buildup (ascites, pleural effusion) requiring drainage - Your cancer has spread widely beyond 5 lesions or 3 organs Talk to your doctor to see if this trial is right for you.